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Abstract
Purpose of Review—To describe the current state of research on interactions between 
inflammation and female sexual function.
Recent findings—Inflammation may interfere with female sexual desire and arousal via direct 
(neural) and indirect (endocrine, vascular, social/behavioral) pathways. There are significant sex 
differences in the effect of inflammation on sexual function, arising from different evolutionary 
selection pressures on regulation of reproduction. A variety of inflammation-related conditions are 
associated with risk of female sexual dysfunction, including cardiovascular disease, metabolic 
syndrome, and chronic pain.
Summary—Clinical implications include the need for routine assessment for sexual dysfunction 
in patients with inflammation-related conditions, the potential for anti-inflammatory diets to 
improve sexual desire and arousal function, and consideration of chronic inflammation as 
moderator of sexual effects of hormonal treatments. Although the evidence points to a role for 
inflammation in the development and maintenance of female sexual dysfunction, the precise 
nature of these associations remains unclear.
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Introduction
Despite much research on interactions between immunity and female reproductive health 
[1], there is much less known about the effect of immunity on women’s sexual wellbeing. 
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The present review examines one important aspect of immune response – inflammation – 
and its potential effects on women’s sexual desire and arousal (see Figure 1 for visual 
summary). While there is much indirect evidence for important interactions between 
inflammation and female sexual function, causal studies are lacking; thus, the broader 
purpose of this review is to encourage future research.
Definition of desire and arousal
Sexual desire is a motivational state, reflecting the interest in or receptiveness to sexual 
activity either with or without a partner [2]. As such, it has been characterized as either an 
acute response to sexual cues [3] (including sexual arousal [4, 5]) or as an ongoing 
orientation towards sexual stimuli [2, 6]. Sexual arousal, on the other hand, is typically 
defined as a temporary state that occurs in response to sexual stimulation. Female sexual 
arousal involves thoughts and emotions as well as physiologic responses including both 
sympathetic nervous system activation (e.g., increased heart rate, blood pressure, and 
breathing rate) and arousal of the sex organs (e.g., engorgement of the vulva and vaginal 
lubrication) [7]. There are common psychological and physiologic foundations for both 
arousal and desire, including some shared neural networks [8, 9]; moreover, in healthy 
females, desire can lead to arousal, and vice versa, in a cyclical feedback loop [5, 10]. 
Insofar as inflammation influences sexual desire, it will likely also impact arousal.
Primer on inflammation
Inflammation is a suite of immune processes that respond to pathogens and toxins, identify 
and clear out damaged cells, and stimulate and direct the adaptive immune system. In the 
acute phase, stimulated immune cells exert a variety of inflammatory actions: increasing 
blood flow and permeability of blood vessels to permit diffusion of plasma into the tissues; 
phagocytosis of pathogens and cellular waste; release of substances such as histamines that 
damage foreign cells; and generation of acute-phase products such as coagulation factors 
and complement proteins. The acute inflammatory response generally resolves rapidly, as it 
relies on the presence of stimulating factors which degrade rapidly as the harmful agents are 
removed. However, if these stimulating factors remain, the inflammatory response evolves to 
a chronic phase that can result in lasting tissue damage, and contributes to future immune 
hypersensitivity and autoimmunity [11, 12] as well as a number of chronic diseases such as 
metabolic and mood disorders [13].
In addition to its critical role in immune defense, inflammation contributes to somatic 
maintenance. For example, many of the tasks faced by the female reproductive system (e.g., 
menstrual cycling [14], ovulation [15], implantation [16], and parturition [17]) rely on 
inflammation processes that assist with tissue repair, vascular reorganization, and 
coordination with endocrine and nervous systems. One of the negative effects of chronic 
inflammation on reproduction is disruption of the normal activity of acute inflammation and 
subsequent loss of these important functions.
Much research on inflammation indexes the level of cytokines, proteins secreted both by 
immune cells (e.g., macrophages) and other tissues (e.g., endothelial cells). Like hormones, 
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these proteins act on receptors to produce an effect, including regulating inflammation 
processes; notably, cytokines can also act on cells outside the immune system such as the 
nervous system (e.g., neurons and microglia [18]) and endocrine system (e.g., gonads [19]). 
Cytokines may exert either a pro- or anti-inflammatory effect, depending on contextual 
factors such as where they are secreted, sender and receiver cell type, and activity of other 
cytokines, hormones, or neurotransmitters. However, there are a few cytokines that are 
typically indexed for their pro- or anti-inflammatory action. The triad of IL-6, IL-1β, and 
tumor necrosis factor-α (TNFα) are thought to have a predominantly pro-inflammatory role 
[20, 21], as each encourages the inflammatory action of macrophages and stimulates the 
production of acute phase proteins and prostaglandins (see below). The action of these 
cytokines on the nervous system are also critical for the psychological and behavioral 
aspects of sickness [22]. In contrast, IL-4 and IL-10 are thought to be anti-inflammatory as 
they inhibit the action of pro-inflammatory cytokine signaling [23] and encourage 
development of Th2 cells, which regulate acute inflammation and moderate tissue damage 
[24, 25].
Another commonly indexed marker of inflammation is C-reactive protein (CRP). Acute-
phase proteins like CRP aid in disposal of dead cells and pathogens by binding to their 
surface and attracting other immune actors to dispose of them. The liver produces CRP in 
response to cytokine signaling from across the body, making it a useful index of system-
level inflammation.
Finally, prostaglandins are compounds that exert a hormone-like effect to moderate 
inflammation processes [26]. Like cytokines, prostaglandins can exert direct action on 
receptors in the nervous system, resulting in pain [27]. Of note, prostaglandin action in the 
central nervous system is an important mediator of anorexia (loss of appetite) associated 
with sickness [28]; there is speculation that prostaglandins may moderate other motivation 
systems as well including, potentially, female sexual desire [29–31]. Outside the brain, 
prostaglandins can serve a pro-sexual role by promoting vasodilation, including that 
associated with genital arousal in both males and females [32].
Mechanisms by which inflammation may influence female sexual desire and arousal 
Central nervous system
Cytokines can exert a powerful effect on the central nervous system, contributing to 
behavioral responses, potentially including sexual response. Areas of the brain that have 
been shown to be relevant for coordination of sexual desire and arousal, such as the 
mesolimbic reward system, cingulate cortex, and thalamus [8, 33], have been shown to 
respond to cytokine signaling, both directly on neuronal receptors [34, 35] and indirectly 
though interactions with dopamine [36] and other neurotransmitters [37, 38]. Several studies 
have found that, even at levels too low to trigger other symptoms such as fever, pro-
inflammatory cytokines can interfere with neural processing associated with motivation and 
reward [39, 40].
A number of animal studies suggest that pro-inflammatory cytokines can lower interest in 
sexual behavior, particularly among females. When given a dose of IL-1β or 
lipopolysaccharide (LPS, a substance that induces robust inflammatory responses), female 
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rats had significantly reduced interest in sexual activity. At an equivalent dose, male rats 
showed no decrease in sexual interest (and, at high doses, even showed increased sexual 
interest) [41, 42]. The desire-suppressing effect of inflammation appears to be the result of 
interactions between multiple cytokine systems, including IL-1β and TNF-α [42, 43], as 
well as increased prostaglandin synthesis and activity in the hypothalamus [31].
These findings have not yet been thoroughly replicated in humans, but preliminary evidence 
suggests convergence. In a small exploratory study of premenopausal women, higher levels 
of CRP and IL-6 predicted lower levels of self-reported sexual desire, arousal and pleasure 
during sexual activity [44]. In contrast, a small study of men found significant positive 
correlations between high sexual desire and TNF-α (but not CRP) [45]. In a separate study 
of 11 healthy men, Haake et al. found sexual arousal was associated with increases in IL-6 
and TNF-α, albeit non-significantly [46]. Together, these findings echo the sex differences 
noted in animal models, with markers of inflammation associated with lower desire and 
arousal in females, but either no effect or higher desire/arousal in males.
Why would the nervous system respond to inflammation cues, and why would there be sex 
differences in the effect of inflammation on sexual desire? There is a suite of behavioral and 
psychological effects induced by increased inflammation, such as fatigue and anhedonia. 
These “sickness behaviors” may have evolved to focus resources on fighting infections by 
lowering activity levels and reducing exposure to new sources of infection (such as other 
animals) [47]. Signals of inflammation may thus reduce interest in all social interactions, 
including partnered sexual activity [48]. Reproduction requires significant resources, more 
so for females than for males [49]. As such, modulation of sexual desire may be a means of 
timing female reproductive investment in accordance with resource availability (or likely 
future availability) [50]. Inflammation processes are energetically costly, precluding long-
term investment in non-essential processes such as reproduction [51]. Thus, signals of 
inflammation may exert a more powerful effect on female sexual desire in order to delay 
reproductive investment to healthier times [52, 53].
The behavioral sequelae of inflammation are not limited to lower female sexual desire; there 
is reason to believe inflammation may inhibit arousal via increased disgust sensitivity. 
Disgust is a form of “behavioral immunity”, reducing the chance of exposure to infection by 
producing an avoidance/withdrawal reaction to disease cues [54, 55]. When inflammation 
levels rise, disgust sensitivity and avoidance reactions become more pronounced [55–57]. 
Disgust can interfere with approach-related emotions, including sexual arousal [58, 59]. 
Experimentally-induced disgust strongly inhibits female sexual arousal [60–62]. At a trait 
level, disgust is associated with higher rates of female sexual desire and arousal dysfunction 
[63]. The reciprocal inhibition between disgust and sexual arousal may be particularly 
evident in females, as the female body faces higher reproductive burden of sexually 
transmitted infection relative to males [58, 64, 65].
Taken together, these findings suggest that inflammation may act on the central nervous 
system to contribute to female sexual desire and arousal dysfunction via interference with 
reward processing (decreasing motivation for sex) and increased disgust (increasing 
avoidance and lowering arousal [65]).
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In addition to the direct effects of cytokines on neural processing, inflammation can 
influence endocrine function. As noted above, there are significant interactions between 
female reproductive and immune systems that are thought to have evolved to balance 
tradeoffs between investing in reproduction vs. somatic maintenance [66]. Alongside direct 
neural effects, these tradeoffs are often negotiated via immune interactions with sex steroid 
hormones (such as estrogens and androgens) and other hormones such as leptin [67, 68] and 
kisspeptin [69]. A decidedly mixed literature has revealed that the normal function of these 
hormones is a necessary, but not sufficient factor in human sexual behavior: while their 
presence does not guarantee sexual function, their absence almost always impairs it.
Estrogens and progesterone—A large body of clinical and basic science research has 
documented the effects of estrogens and progesterone on inflammation. Notably, the action 
of each hormone depends the level expressed, and the presence of the other [70–72]. At high 
levels (e.g., during pregnancy) estrogens typically have an anti-inflammatory action, by 
inhibiting production of pro-inflammatory cytokines [73] such as IL-6 and TNF-α [74–77], 
stimulating production of anti-inflammatory cytokines such as IL-4 and IL-10 [78], and 
accelerating the resolution of ongoing inflammation [79]. However, at lower levels estrogens 
can be pro-inflammatory as they stimulate production of IL-1β [80, 81] and increase the 
inflammatory action of neutrophils and monocytes [82, 83]. Progesterone is typically weakly 
anti-inflammatory [84], but in the presence of high levels of estradiol, can exert powerful 
inhibitory effects on macrophage-mediated inflammation processes [85, 86].
In turn, inflammatory processes suppress production of sex steroid hormones and can 
modulate the action of their receptors. Inflammation processes inhibit hypothalamic release 
of gonadotropin releasing hormone (GnRH) [87, 88], which in turn reduces production of 
gonadal hormones. Concurrently, pro-inflammatory cytokines activate the hypothalamic-
pituitary-adrenal (HPA) axis via increased production of adrenocorticotropin releasing 
hormone [89], which further antagonizes production of GnRH [90]. More directly, TNF-α 
and IL-1β inhibit production of progesterone and estradiol by ovaries [91–93], uterus [94], 
and breast tissue [95]. Women who have high circulating levels of IL-6 and IL-1β show 
significantly lower GnRH receptor sensitivity [96]. In animal models, inflammation is 
associated with reduction in the number and sensitivity of the estrogen receptor-α (ERα) 
[97]. In sum, inflammation can interfere with synthesis and activity of estrogen and 
progesterone, reducing their potentially stimulatory effect on female sexual desire and 
arousal.
It should be noted that effect of estrogens and progesterone on inflammation appear to differ 
if these hormones are endogenous (i.e., those produced by the body) vs. exogenous 
(administered). Whereas endogenous estrogens can have an anti-inflammatory effect, use of 
exogenous estrogens are associated with increased levels of inflammation, particularly when 
administered orally [70, 98–100]. There is no consensus as to the effect of hormonal 
treatments (such as oral contraceptives or hormone replacement therapies) on sexual desire 
and arousal in healthy women [101, 102]. However, a number of studies have documented 
that at least a subset of patients report either decreased sexual desire [103–105] or lack of 
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improvement in sexual desire [106, 107] while taking these medications. Given the strong 
associations between endocrine and immune systems, it is likely that inflammatory effects 
partially mediate some of the negative effects of estrogen and progesterone treatments on 
women’s sexual desire and arousal; clearly, this is an area needing further research.
Testosterone—Early work characterized testosterone and other androgens as universally 
immunosuppressant, as males typically have lower immune response (and lower rates of 
autoimmune disorders) than do females [108]. It is now clear that, like estrogens, 
endogenous androgens can have either pro- or anti-inflammatory actions in females, 
depending on menstrual cycle phase [109], menopausal status [110–114], and even level of 
sexual activity [115]. Treatment with exogenous testosterone similarly can have either a pro- 
or anti-inflammatory effect, again depending on menstrual cycle phase and/or menopausal 
status [109, 116, 117]. Studies of androgen treatment in hypogonadal women have found no 
significant effect of testosterone on CRP [118, 119] or other markers of inflammation [120]. 
In the other direction, inflammation is known to reduce gonadal production of testosterone 
[121, 122] (except in the case of polycystic ovarian syndrome [123]). Moreover, high levels 
of IL-6 and TNF-α stimulate aromatase activity [124, 125], which converts testosterone to 
estrogen, further decreasing bioavailable testosterone.
There have been similarly inconsistent reports of the effects of testosterone on female sexual 
desire and arousal function: some studies have found significant positive associations [126–
128], others negative [129, 130], and others no association [131, 132]. Of note, women who 
are regularly sexually active with a partner have lower endogenous testosterone than single 
(and sexually inactive) women [133, 134]. Systematic reviews suggest that while 
testosterone treatment for low libido can be effective in postmenopausal women [135, 136], 
it is not significantly better than placebo for premenopausal women with normal gonadal 
function [137, 138]. The inconsistency across both lines of literature makes it difficult to 
draw definite conclusions regarding the interactions among testosterone, inflammation and 
female sexual desire; however, it is clear that these interactions will be sensitive to 
contextual factors such as menopausal status, menstrual cycle phase, and sexual partnership.
Oxytocin—Finally, oxytocin plays an important role in female sexual function, as it is 
released during sexual arousal and orgasm [139], and contributes to the sense of intimacy 
and pleasure associated with sexual activity [140, 141]. Women with low scores on the FSFI 
arousal and lubrication subscales have lower levels of oxytocin than women who are 
satisfied with their sexual function [142]. In addition to its role in coordinating sociosexual 
behavior, oxytocin reduces the level of pro-inflammatory cytokines produced by 
macrophages [143, 144] and microglial cells of the nervous system [145]. Thus, it is 
possible that the high levels of oxytocin associated with sexual activity (and particularly 
with orgasm) may provide a permissive environment for sexual desire by reducing cytokine 
signaling in the nervous system.
Other mechanisms
Endothelial dysfunction—One of the ways in which inflammation serves immune 
defense is by encouraging local blood vessels to dilate and increase permeability; this allows 
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defensive and wound-healing factors from plasma to perfuse the inflamed tissue [146]. 
However, chronically high inflammation can interfere with nitric-oxide mediated 
vasodilation, which is necessary for genital arousal [147]. In males, high levels of TNF-α 
and IL-6 are associated with erectile dysfunction [148–150], even when controlling for a 
variety of other factors such as age, metabolic syndrome and blood pressure [151]. 
Specifically, TNF-α has been demonstrated to reduce synthesis of nitric oxide in erectile 
tissue [152], reducing the capacity to support genital arousal. To date, these effects have not 
been replicated in females; however, given similar mechanisms underlying erectile function 
in the penis and the clitoris [153], it is very likely that high levels of TNF-α would interfere 
with genital arousal function in females.
Sexual pain—One of the key clinical signs of inflammation is pain (dolor), and thus it is 
not surprising that women who report significant pain with penetration also have elevated 
markers of inflammation, both locally in the vulva and vagina [154] and systemically [155, 
156]. Women with sexual pain disorders report significantly lower sexual desire and arousal 
than women without such disorders [157]. Thus, it is reasonable to expect that to the degree 
that inflammation contributes to pain during sex, it will also contribute to lower sexual 
desire.
Attractiveness—In rodent models, males are significantly less likely to initiate or be 
receptive to sexual activity with a female who has been treated with IL-1β [158] or LPS 
[159], suggesting that the attractiveness of potential sexual partners was reduced when they 
were expressing higher levels of inflammation. From an evolutionary perspective, mating 
with an unhealthy female can be both risky (in terms of potential exposure to infection) and 
counterproductive (in terms of likelihood of spontaneous abortion). Humans are similarly 
able to detect experimentally-induced increases in inflammation via olfactory and visual 
cues [160, 161]. In one study, the faces of participants who had been injected with LPS were 
rated significantly less sexually attractive than the faces of the same participants following 
saline injection [162]. Insofar as sexual desire can be responsive to partner initiation [163], 
these findings suggest that individuals who are expressing higher levels of inflammation 
may experience less interest from their partners, and in turn, less desire themselves.
Sexual desire and arousal function in populations with inflammation-related conditions
Further evidence of the negative impact of chronic inflammation on female sexual desire and 
arousal function comes from clinical observations in populations with inflammation-related 
conditions. In each case, sexual desire appears to be impacted more severely than other 
aspects of sexual function such as orgasm.
Cardiovascular disease (CVD)—There is a well-known connection between CVD and 
erectile dysfunction in men [164], which is mediated via chronic inflammation and 
subsequent endothelial dysfunction [165–167]. Although less well documented, the 
associations among inflammation, CVD, and sexual arousal dysfunction have also been 
observed in women [168–170]. Similarly, hypertensive women report lower sexual desire 
and arousal function than normotensive women [171], although it should also be noted that 
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anti-hypertensive medications are known to have iatrogenic effects on sexual function [171, 
172].
Metabolic syndrome—Chronic low-grade inflammation is also associated with obesity 
and metabolic syndrome, as adipose tissue generates pro-inflammatory cytokines which in 
turn impair insulin sensitivity [173]. Across numerous studies, metabolic syndrome is 
associated with significantly higher levels of sexual desire dysfunction among women [174–
176]. In studies that include both pre- and post-menopausal women, there are higher rates of 
sexual desire dysfunction among women with metabolic syndrome than in women without; 
however, arousal and orgasm function are similar across groups [177, 178]. In one study of 
women with and without metabolic syndrome, scores on a validated index of sexual function 
were inversely related to levels of serum CRP [179], further evidence that inflammation may 
partially mediate the higher rates of sexual dysfunction in women with metabolic syndrome.
Chronic pain—Although the etiology of chronic pain is complex, there are many pain 
conditions for which inflammation plays a significant role [180]. There are higher rates of 
sexual desire and arousal dysfunction among women with inflammatory bowel diseases 
[181, 182], rheumatoid arthritis [183], fibromyalgia [184], and chronic pelvic pain [185]. 
Among women with rheumatoid arthritis, sexual desire and arousal dysfunction is predicted 
by higher levels of CRP [186].
Effects of anti-inflammatory treatments on female sexual function
As noted above, inflammation-related conditions can have a deeply negative effect on 
female sexual function. However, the effect of treatments for these conditions have mixed 
effects on sexual function: while anti-inflammatory diets and lifestyle interventions appear 
to have a positive effect, anti-inflammatory medications can have a negative effect. In 
considering this paradox, it should be noted that cytokines and prostaglandins have a variety 
of homeostatic functions not limited to inflammation per se [187]; external manipulation of 
these systems may have iatrogenic effects that environmental or behavioral interventions 
lack.
Non-steroidal anti-inflammatories (NSAIDS)
In men, long-term use of NSAIDs has been associated with erectile dysfunction, both in 
exaggeration of pre-existing sexual dysfunction as well as new onset cases. Two studies 
found the association attenuated when considering patient’s underlying medical conditions 
[188, 189]; however, others have found increased risk even when controlling for indication 
and age [190, 191]. NSAIDs have their therapeutic action via inhibition of cyclooxygenase 
(COX) synthesis, which in turn reduces the activity of prostaglandins [192]. However, this in 
turn may interfere with prostaglandin-mediated vasodilation of erectile tissue [193]. The 
effect of NSAIDs on female sexual arousal is unknown. Given similar mechanisms of 
clitoral and penile erection [153], it is likely that NSAIDs would interfere with female 
sexual arousal as they do in males. However, in animal models, prostaglandins strongly 
suppressed female but not male sexual desire [31], suggesting potentially different effects 
across domains of female sexual function.
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The Mediterranean diet – emphasizing whole grains, fresh fruits and vegetables, fish and 
poly-unsaturated fats – has been demonstrated to reduce markers of inflammation in both 
healthy weight [194, 195] and overweight women [196]. A Mediterranean diet has also 
shown benefits for sexual function for women with metabolic syndrome, particularly in 
sexual desire and arousal function [197–200]; these gains are mediated by decreased levels 
of CRP [197] (but see also [198]). Similarly, a calorie-restricted diet (also shown to reduce 
chronic inflammation [201]) has been shown to increase sexual desire and arousal in 
overweight women [202].
Clinical implications
Taken together, the above research strongly suggests that inflammation may play a 
significant role in female sexual desire and arousal function – although the precise nature of 
that role is still unknown. Thus, the following clinical implications should be considered 
speculative but worthy of future research.
Reducing chronic exposure to systemic inflammation is associated with improvements 
across a variety of domains of health and wellbeing; it is reasonable to suspect benefits for 
sexual function as well. As noted above, preliminary data strongly suggest that anti-
inflammatory diets improve sexual desire and arousal, particularly among overweight 
women; given their high potential benefit and low risk of harm, these diets may be 
recommended as a preventive first-line treatment or adjunctive to treatments for sexual 
desire or arousal concerns. It is also reasonable to consider chronic inflammation as a 
possible contributing factor when assessing sexual desire and arousal concerns, particularly 
in women with immune conditions and in overweight women. Given interactions between 
immune and endocrine systems, it may be worthwhile to monitor changes in circulating 
markers of inflammation when introducing hormone regimens intended to treat sexual 
dysfunction; if a hormonal treatment stimulates desire through central mechanisms, but also 
increases systemic inflammation, the final result may be less dramatic than hoped. Finally, it 
is commonly accepted that, in men, sexual dysfunction may be an early warning sign of 
inflammation-related conditions such as CVD [203–205]; although much further research is 
needed, the evidence points to the same being true of women [206], suggesting benefits for 
routine assessment of female sexual desire and arousal function in the context of 
preventative care.
Conclusions
Chronic inflammation can contribute to dysfunction across metabolic, cardiovascular, 
endocrine, and neurological systems. Thus, it is not surprising that inflammation may impact 
female sexual function. However, women’s sexual desire and arousal may be particularly 
sensitive to the effects of inflammation, owing to the important interactions between female 
reproductive and immune systems. The aggregate evidence suggests that inflammation may 
interfere with female sexual desire and arousal by both direct (neural) and indirect 
(endocrine, endothelial, social/behavioral) mechanisms. However, this evidence comes 
mostly from animal studies, studies in males, and observations of higher rates of sexual 
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dysfunction among clinical populations characterized by chronic inflammation. Direct 
evidence of the effects of inflammation on female sexual function is lacking. Future research 
elucidating the interactions between sexuality and immune function will likely be quite 
fruitful in uncovering new avenues for treatment for female sexual dysfunction
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Summary of research on inflammation and female sexual desire and arousal function.
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